Curious about Moderna (MRNA) Q2 Performance? Explore Wall Street Estimates for Key Metrics

The upcoming report from Moderna (MRNA) is expected to reveal quarterly loss of -$2.99 per share, indicating an increase of 10.2% compared to the year-ago period. Analysts forecast revenues of $127.17 million, representing a decline of 47.2% year over year.The consensus EPS estimate for the quarter has undergone a downward revision of 1.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.With that in mind, let's delve into the average projections of some Moderna metrics that are commonly tracked and projected by analysts on Wall Street.Analysts forecast 'Revenue- Net Product sales' to reach $81.42 million. The estimate indicates a change of -55.8% from the prior-year quarter.The consensus estimate for 'Revenue- Other revenue' stands at $25.13 million. The estimate indicates a year-over-year change of -55.9%.The consensus among analysts is that 'Product sales- United States' will reach $28.31 million. The estimate points to a change of -82.5% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Product sales- Rest of world' of $42.95 million. The estimate points to a change of +95.2% from the year-ago quarter. View all Key Company Metrics for Moderna here>>> Over the past month, Moderna shares have recorded returns of +22.9% versus the Zacks S&P 500 composite's +3.6% change. Based on its Zacks Rank #3 (Hold), MRNA will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Higher. Faster. Sooner. Buy These Stocks NowA small number of stocks are primed for a breakout, and you have a chance to get in before they take off.At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We’ve combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month.You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days.Download the report free now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Moderna, Inc. (MRNA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks